Cyberonics reiterated at 'outperform'
The major neuromodulation company's growth strategies appear to be working.
By Zacks Equity Research
We recently maintained our "outperform" recommendation on Cyberonics (CYBX), a major neuromodulation company, with a target price of $63.00.
The recommendation is primarily based on the company's strong future growth prospects. Over the last few quarters, Cyberonics has consistently delivered strong results through balanced sales growth worldwide. In the last-reported quarter, total sales increased a robust 17% year-over-year to $63.0 million and adjusted earnings grew 37.5% to 44 cents per share. The results surpassed the Zacks consensus estimates of $60 million and $0.39, respectively.
The upside in revenues -- representing the second successive quarter of over $50 million in sales -- was primarily attributable to robust growth in the U.S. epilepsy device sales, which increased by 16%, and unit sales, which rose by 12.3%. The redesigned AspireHC generator that received Food and Drug Administration approval in January, 2012, comprised 17% of the U.S. generator unit sales in the reported quarter. Over 77% of the U.S. generator sales came from Demipulse and AspireHC. We expect all these product lines to boost Cyberonics' top-line performance in the upcoming quarters.
After a couple of quarters of sluggish international sales, the company recorded robust sales growth of 28.3% outside its domestic market, favorably impacted by double-digit sales growth in Europe, increased shipments to Japan, as well as improved sales in all other international regions. Cyberonics remains positive about its initiatives to invest in market development and achieve new patient and replacement cycle growth in Europe and Japan, which are expected to further improve the company's performance in these regions.
In Europe, the company's increased investments and organizational changes have proved helpful, which was reflected in the double-digit growth in overall performance for the third consecutive quarter. Moreover, the company deployed senior sales and marketing teams from the U.S. in Europe and Japan to strengthen the organization. Cyberonics expects all these initiatives to improve its international performance for the rest of fiscal 2013.
Cyberonics is also focusing on strengthening its pipeline. The company is currently working on the development of future generations of the Vagus Nerve Stimulation Therapy System, which includes generators that utilize cardiac and brain-based seizure detection stimulation paradigms, rechargeable battery technology, wireless communication technology and improved lead technology.
We remain concerned about the challenging macroeconomic scenario and competitive pressures from players like Medtronic (MDT) and St. Jude (STJ) in the neuromodulation space. However, considering the advantages of the VNS therapy system and the strong untapped potential in the epilepsy market, we are optimistic about the growth prospects of the company.
Cyberonics carries a Zacks #2 Rank (Buy) in the short term.
More from Zacks.com
Copyright © 2014 Microsoft. All rights reserved.
As geopolitical tensions threaten to spin out of control, investors are wondering how best to position their portfolios for the global turmoil.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.